The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Mon., Jul. 4, 11:36 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #70. Charles River Laboratories International, Inc. Vital River

Acquirer: Charles River Laboratories International, Inc. (NYSE:CRL)
Acquiree: Vital River
Details: Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has completed its acquisition of a 75% ownership of Vital River, the premier commercial provider of research models and related services in China, and a licensee of Charles River for the last ten years.

Charles River Laboratories International is a contract research organization. Co. has a laboratory animal medicine and science to develop a portfolio of discovery and safety assessment services. Co.'s segments include: Research Models and Services, which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides DSA services, including in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development; Manufacturing Support, which ensure the safe production and release of products manufactured by Co.'s clients.

CRL SEC Filing Email Alerts Service

Open the CRL Page at The Online Investor »

Company Name: 
Charles River Laboratories International Inc.
Number of ETFs Holding CRL: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the CRL Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree CRL Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.59 out of 4)
51st percentile
(ranked higher than approx. 51% of all stocks covered)

Analysts' Target Price:
CRL Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 70 of 83 Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.